SOURCE: Protherics PLC

January 24, 2007 13:08 ET

Protherics PLC announces Appointment

Cheshire, UK -- (MARKET WIRE) -- January 24, 2007 --

                                 Protherics PLC

                     Appointment of Non-executive Director

London, UK; Brentwood, TN, US; 24 January 2007 - Protherics PLC ("Protherics" or
the "Company"), the international biopharmaceutical company focused on critical
care and cancer, is pleased to announce the appointment of Dr Jacques Gonella as
a non-executive director, with effect from today.  He will serve on the
Company's audit, nomination and remuneration committees.

Dr Gonella served on the Board of MacroMed, Inc. from 1999 until its acquisition
by Protherics on 4 January 2007.  He is the principal in the consulting firm of
JG Consulting AG and is the founder of Permatec Pharma AG, which merged with
Mediject in 2001 to form Antares Pharma, Inc., a US public specialty pharma
company.  He also serves as Chairman of the Board of Directors of Antares
Pharma.  Prior to founding Permatec, Dr Gonella founded JAGO Pharma AG in 1983
and served as its president and CEO until its acquisition in May 1996 by
SkyePharma PLC.  Before founding JAGO, he occupied various positions with F.
Hoffmann La Roche Ltd. and Pfizer, Inc. between 1968 and 1979.

Dr Gonella holds 8,245,815 ordinary shares of 2p each in the capital of the
Company which he received as consideration upon the acquisition of MacroMed Inc.
by Protherics.

There are no further details to be disclosed in relation to Paragraph 9.6.13R of
the Financial Services Authority Listing Rules.

                                   |  Ends  |

For further information please contact:

Nick Staples, Director of Corporate Affairs               +44 (0) 7919  480510
Julie Vickers, Company Secretary                            +44 (0)1928 518010

Financial Dynamics - press enquiries
London: Ben Atwell, Anna Keeble                           +44 (0) 20 7831 3113
New York: John Capodanno, Jonathan Birt                        +1 212 850 5600

Or visit

                      This information is provided by RNS
            The company news service from the London Stock Exchange